The global Rapid Microbiology Testing market gathered revenue around USD 8.2 Billion in 2020 and market is set to grow USD 3.8 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 11% during the prediction period 2021 to 2027.
Overview of Rapid Microbiology Testing Market Study
Rapid Microbiology Testing market study conducted by Nova One Advisor is intended at helping stakeholders get a comprehensive overview of potential challenges and undiscovered opportunities. The report offers exclusive insights to help companies and their customers to make informed decision to sustain growth through the assessment period.
Get your Customized Research Report@ https://www.novaoneadvisor.com/report/customization/4477
Market growth is driven by the increased focus on the early detection of infectious disease, technological advancements, increased funding for R&D and increasing incidence of infectious disease.
Driver: Increasing incidence of infectious disease and cancer.
The incidence of various infectious diseases such as HIV, tuberculosis, malaria, and pneumonia has increased. With a rise in the global burden of these diseases, the demand for rapid microbiology techniques for faster and accurate microbial screening, identification, and susceptibility testing against pathogens is expected to witness significant growth during the forecast period
Opportunity: Growth opportunities in emerging countries
Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the rapid microbiology testing market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infectious diseases, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries has drawn key players in the rapid microbiology testing market to focus on emerging countries.
Restraint: High capital investments and low cost-benefit ratio.
Significant capital investments are required for the discovery, development, and validation of efficient rapid tests. Additionally, due to the high drug attrition in clinical trials (with almost 30% of drugs failing in Phase III), diagnostic manufacturers are exposed to significant financial challenges. To gain approval for in vitro diagnostics (IVD) from regulators, manufacturers need successful Phase III clinical trials. Huge investments are required to run clinical trials and address stringent regulatory requirements, which not only affects the ability of small companies to develop tests but also severely affects innovation. Hence, along with the high amount of capital investments, the low cost-benefit ratio is hindering the growth of the rapid microbiology testing market.
Challenge: Operational barriers
Clinical laboratories across major markets are still evolving; technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as NGS and lab-on-a-chip PCR devices. Laboratory space also needs to be reconfigured to meet the requirements of conducting specific diagnostic tests used for pathogen detection as a means of avoiding cross-contamination and ensuring efficient time management. This results in considerable cost escalation to maintain and operate advanced rapid microbiology tests, particularly those capable of handling a single sample type. Furthermore, due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis.
“In 2020, instruments accounted for the largest share of the rapid microbiology testing market, by product”
The rapid microbiology testing market is segmented into instruments, reagents and kits and consumables based on product. The instrument segment accounted for the largest share of the rapid microbiology testing market in 2020, mainly due to the increased funding for R&D, increasing incidence of infectious disease and cancer and technological advancements.
“In 2020, growth-based rapid microbiology testing segment accounted for the largest share in the market, by method”
The rapid microbiology testing market is segmented into growth-based, cellular-based, nucleic acid-based, viability-based and other rapid microbiology testing based on method. In 2020, the growth-based rapid microbiology testing segment accounted for the largest share. Factors such as increased focus on the early detection of infectious disease increased funding for R&D and increased incidence of infectious disease and cancer.
“In 2020, clinical disease diagnosis segment accounted for the largest share in the market, by applications”
The rapid microbiology testing market has been segmented into clinical disease diagnosis, food and beverage testing, pharmaceutican and biological drug testing, environmental testing, cosmetics and personal care products testing , research applications and other applications based on applications. In 2020, the clinical disease diagnostics segment accounted for the largest share of the rapid microbiology testing market. The increasing incidence of infectious disease and cancer is driving the growth of this segment.
“North America is the largest regional market for rapid microbiology tests”
The global rapid microbiology testing market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global rapid microbiology testing market. The North American rapid microbiology testing market’s growth can be attributed to the, increased funding for R&D, increased focus on the early detection of infectious disease and increased incidence of infectious disease and cancer.
Buy Complete Assessment of Rapid Microbiology Testing market Now@ https://www.novaoneadvisor.com/report/checkout/4477
COVID-19 Impact on Rapid Microbiology Testing Sales
Businesses today are operating in a dynamic environment. Earlier focus primarily concentrated on keeping pace with changing consumer preferences. COVID-19 outbreak was unprecedented and exposed vulnerabilities of various industries. Pandemic-induces obstacles also were registered in the Rapid Microbiology Testing market.
Sales plummeted as COVID-19 gradually tightened its noose worldwide. Supply-chain disruptions caused massive losses, while demand took nose-dive as consumers remained indoors with affected countries implementing either partial or complete lockdown.
Gradual recovery however is on the cards with the roll out of vaccinations. Nonetheless, consecutive waves of the virus compelled businesses to stay prepared for the worst. As government and healthcare organizations successfully implement steps to contain the spread of COVID-19, industries have begun operations, albeit at a slow and more cautious pace.
Against this backdrop, Nova one advisor’s study predicts gradual recovery for the Rapid Microbiology Testing market 2021 onwards. This trend will however continue through the course of the report’s assessment period
This report provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the Rapid Microbiology Testing market and ranks noticeable companies as per their occurrence in diverse regions across globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.
Some of the prominent players in the Rapid Microbiology Testing market include:
Abbott Laboratories, Inc. (US), Becton, Dickinson and Company (US), bioMérieux SA (France), Bruker Corporation (US), Charles River Laboratories International, Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), NEOGEN Corporation (US), Quidel Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific, Inc. (US), Don Whitley Scientific Limited (UK), Rapid Micro Biosystems, Inc. (US), Vivione Biosciences, LLC (US), Gradientech (Sweden), rqmicro AG (Switzerland), Bactest Ltd. (US), Colifast (Norway), Serosep Ltd. (Ireland), Biosensia (Ireland), Solus Scientific Solutions Ltd. (Scotland), LubioScience GmbH (Scotland), Euroclone SpA (Italy), CorDx (US), and R-Biopharm AG (Germany).
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
- Automated Microbial Identification & Antimicrobial Susceptibility Testing System
- Mass Spectrometers
- Bioluminescence & Fluorescence-Based Detection System
- PCR Systems
- Active Air Samplers
- Other Instruments
- Reagents and Kits
- Sterility Reagents and Kits
- Other Reagents and Kits
- Growth-Based Rapid Microbiology Testing
- Cellular component-Based Rapid Microbiology Testing
- Nucleic Acid-Based Rapid Microbiology Testing
- Viability-Based Rapid Microbiology Testing
- Clinical Disease Diagnostics
- Food & Beverage testing
- Pharmaceutical & Biological Drug Testing
- Environmental Testing
- Cosmetics and Personal Care Products Testing
- Research Applications
- Other Applications
Why Buy this Report?
The purpose of Nova one advisor’s Rapid Microbiology Testing market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.
Download This Full Research Report, Click Here@ https://www.novaoneadvisor.com/report/checkout/4477
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
Call: +1 9197 992 333